AP3283A - N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors - Google Patents

N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Info

Publication number
AP3283A
AP3283A AP2012006269A AP2012006269A AP3283A AP 3283 A AP3283 A AP 3283A AP 2012006269 A AP2012006269 A AP 2012006269A AP 2012006269 A AP2012006269 A AP 2012006269A AP 3283 A AP3283 A AP 3283A
Authority
AP
ARIPO
Prior art keywords
coa carboxylase
carboxylase inhibitors
pyrazolospiroketone
acetyl
pyrazolospiroketone acetyl
Prior art date
Application number
AP2012006269A
Other languages
English (en)
Other versions
AP2012006269A0 (en
Inventor
Scott William Bagley
David Andrew Griffith
Daniel Wei-Shung Kung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2012006269A0 publication Critical patent/AP2012006269A0/xx
Application granted granted Critical
Publication of AP3283A publication Critical patent/AP3283A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2012006269A 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors AP3283A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10
PCT/IB2010/054908 WO2011058474A1 (fr) 2009-11-10 2010-10-29 Inhibiteurs de n1-pyrazolospirocétone acétyl-coa carboxylase

Publications (2)

Publication Number Publication Date
AP2012006269A0 AP2012006269A0 (en) 2012-06-30
AP3283A true AP3283A (en) 2015-05-31

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006269A AP3283A (en) 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Country Status (39)

Country Link
US (4) US8288405B2 (fr)
EP (3) EP2499139B1 (fr)
JP (1) JP5114610B1 (fr)
KR (2) KR101478517B1 (fr)
CN (1) CN102695708B (fr)
AP (1) AP3283A (fr)
AR (1) AR078944A1 (fr)
AU (1) AU2010317501B2 (fr)
BR (1) BR112012011072A2 (fr)
CA (1) CA2778886C (fr)
CL (1) CL2012000999A1 (fr)
CO (1) CO6541569A2 (fr)
CR (1) CR20120190A (fr)
CU (1) CU24077B1 (fr)
DK (1) DK2499139T3 (fr)
DO (1) DOP2012000128A (fr)
EA (1) EA020153B1 (fr)
EC (1) ECSP12011880A (fr)
ES (1) ES2444543T3 (fr)
GE (1) GEP20146169B (fr)
HN (1) HN2012000973A (fr)
HR (1) HRP20140025T1 (fr)
IL (1) IL219373A (fr)
MA (1) MA33734B1 (fr)
MX (1) MX2012005429A (fr)
NI (1) NI201200089A (fr)
NZ (1) NZ599815A (fr)
PE (1) PE20121469A1 (fr)
PH (1) PH12012500903A1 (fr)
PL (1) PL2499139T3 (fr)
PT (1) PT2499139E (fr)
RS (1) RS53156B (fr)
SI (1) SI2499139T1 (fr)
TN (1) TN2012000192A1 (fr)
TW (1) TWI394756B (fr)
UA (1) UA102336C2 (fr)
UY (1) UY33020A (fr)
WO (1) WO2011058474A1 (fr)
ZA (1) ZA201204231B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
EP2448938B9 (fr) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones comme inhibiteurs de pi3k
UA102336C2 (uk) 2009-11-10 2013-06-25 Пфайзер Інк. N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
WO2011075643A1 (fr) 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
EP2345643A1 (fr) * 2009-12-29 2011-07-20 Polichem S.A. Nouveaux dérivés de 8-hydroxyquinoline-7-carboxamide et leurs utilisations
EP2558463A1 (fr) 2010-04-14 2013-02-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de i3
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
DK2621493T3 (en) * 2010-09-30 2016-10-24 Pfizer N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS
CN103189377B (zh) 2010-10-29 2015-02-25 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
EA022375B1 (ru) * 2011-04-22 2015-12-30 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ
MX389479B (es) 2011-09-02 2025-03-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
EP2961746B1 (fr) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2
CA2903081A1 (fr) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Inhibiteurs d'histone demethylase
MX2016002479A (es) 2013-09-12 2016-05-31 Pfizer Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
EP3670496A3 (fr) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Inhibiteurs de acc2
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA2961525A1 (fr) 2014-09-16 2016-03-24 Celgene Quanticel Research, Inc. Inhibiteurs de l'histone demethylase
SG11201702119PA (en) * 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
US10889903B2 (en) 2014-11-10 2021-01-12 National University Corporation Yokohama National University Oxygen-generating anode
SG10201912302VA (en) 2015-02-27 2020-02-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
ES2982341T3 (es) 2017-06-30 2024-10-15 Quixgen Inc Nuevos compuestos de espirolactona
EP3713942B8 (fr) 2017-11-21 2023-04-12 Pfizer Inc. Sel cristallin de 2-amino-2-(hydroxyméthyl)propane-1,3-diol de l'acide 4-(4-(1 -isopropyl-7-oxo-1,4,6,7-tétrahydrospiro[indazole-5,4'-pipéridine]-1'-carbonyl)-6-méthoxypyridin-2-yl)benzoïque
US11465991B2 (en) 2018-03-15 2022-10-11 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
KR20230013126A (ko) 2020-05-21 2023-01-26 시오노기 앤드 컴파니, 리미티드 지방성 간질환의 치료용 의약
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
JPWO2023090411A1 (fr) 2021-11-19 2023-05-25
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法
US12655157B2 (en) * 2022-07-29 2026-06-16 Pfizer Inc. Spiro[benzo[d]thiazole-6 ,4′-piperidine as ACC inhibitors
WO2025133948A1 (fr) * 2023-12-21 2025-06-26 Pfizer Inc. Inhibiteurs de l'acétyl coa-carboxylase (acc)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011809A1 (fr) * 2005-07-19 2007-01-25 Merck & Co., Inc. Derives de spirochromanone utilises en tant quinhibiteurs d'acetyle coenzyme a carboxylase
EP1911753A1 (fr) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Composé spiro-cyclique
WO2008065508A1 (fr) * 2006-11-29 2008-06-05 Pfizer Products Inc. Inhibiteurs de la spirocétoneacétyl-coa carboxylase
WO2008088689A1 (fr) * 2007-01-12 2008-07-24 Merck & Co., Inc. Dérivés substitués de spirochromanone en tant qu'inhibiteurs d'acc
WO2008125945A2 (fr) * 2007-04-12 2008-10-23 Pfizer Inc. Nouveaux derives de 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h.6h) carbaldehyde
WO2009014455A1 (fr) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Système de prévision du temps de réponse à un courrier électronique
EP2123652A1 (fr) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2009144554A1 (fr) * 2008-05-28 2009-12-03 Pfizer, Inc. Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
CA2439152C (fr) 2001-02-28 2008-06-17 Merck & Co., Inc. Derives de piperidine acylee tels que les agonistes du recepteur 4 de la melanocortine
WO2003072197A1 (fr) 2002-02-27 2003-09-04 Pfizer Products Inc. Inhibiteurs de l'acetyl-coa-carboxylase
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005113069A2 (fr) 2004-05-14 2005-12-01 Research Development Foundation Utilisation de curcumine et d'analogues de curcumine comme inhibiteurs de l'acc2
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
CA2629406A1 (fr) 2005-11-18 2007-05-31 Merck & Co., Inc. Antagonistes du recepteur cgrp de spirohydatoin aryle
US8735595B2 (en) 2006-02-15 2014-05-27 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
EP2297164A1 (fr) * 2008-05-28 2011-03-23 Pfizer Inc. Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
EP2307422B1 (fr) 2008-07-04 2014-03-26 Msd K.K. Nouveaux acides spirochromanone carboxyliques
EP2310015A4 (fr) * 2008-07-14 2011-10-26 Cropsolution Inc Modulateurs de l acétyl-coenzyme a carboxylase et procédés d utilisation associés
NZ591615A (en) * 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
UA102336C2 (uk) * 2009-11-10 2013-06-25 Пфайзер Інк. N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
CA2778316A1 (fr) 2009-11-10 2011-05-19 Pfizer Inc. Inhibiteurs de n-2 pyrazolospirocetone acetyl-coa carboxylase
DK2621493T3 (en) 2010-09-30 2016-10-24 Pfizer N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS
EA022375B1 (ru) * 2011-04-22 2015-12-30 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011809A1 (fr) * 2005-07-19 2007-01-25 Merck & Co., Inc. Derives de spirochromanone utilises en tant quinhibiteurs d'acetyle coenzyme a carboxylase
EP1911753A1 (fr) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Composé spiro-cyclique
WO2008065508A1 (fr) * 2006-11-29 2008-06-05 Pfizer Products Inc. Inhibiteurs de la spirocétoneacétyl-coa carboxylase
WO2008088689A1 (fr) * 2007-01-12 2008-07-24 Merck & Co., Inc. Dérivés substitués de spirochromanone en tant qu'inhibiteurs d'acc
EP2123652A1 (fr) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2008125945A2 (fr) * 2007-04-12 2008-10-23 Pfizer Inc. Nouveaux derives de 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h.6h) carbaldehyde
WO2009014455A1 (fr) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Système de prévision du temps de réponse à un courrier électronique
WO2009144554A1 (fr) * 2008-05-28 2009-12-03 Pfizer, Inc. Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase

Also Published As

Publication number Publication date
UA102336C2 (uk) 2013-06-25
RS53156B (sr) 2014-06-30
MX2012005429A (es) 2012-06-19
US20130296319A1 (en) 2013-11-07
TW201127838A (en) 2011-08-16
CN102695708A (zh) 2012-09-26
AU2010317501B2 (en) 2013-06-06
BR112012011072A2 (pt) 2017-06-20
KR101478517B1 (ko) 2015-01-02
GEP20146169B (en) 2014-09-25
US8288405B2 (en) 2012-10-16
PE20121469A1 (es) 2012-11-01
CU24077B1 (es) 2015-03-30
US20140288111A1 (en) 2014-09-25
EP2499139A1 (fr) 2012-09-19
KR20140034919A (ko) 2014-03-20
US20110111046A1 (en) 2011-05-12
CL2012000999A1 (es) 2012-07-20
NI201200089A (es) 2012-08-20
JP5114610B1 (ja) 2013-01-09
CO6541569A2 (es) 2012-10-16
DOP2012000128A (es) 2012-08-31
CN102695708B (zh) 2014-10-15
EP2499139B1 (fr) 2013-12-11
AR078944A1 (es) 2011-12-14
EP2676958A1 (fr) 2013-12-25
UY33020A (es) 2011-06-30
ECSP12011880A (es) 2012-07-31
EP2947082A1 (fr) 2015-11-25
HN2012000973A (es) 2015-03-02
CA2778886A1 (fr) 2011-05-19
AP2012006269A0 (en) 2012-06-30
WO2011058474A8 (fr) 2012-04-26
DK2499139T3 (da) 2014-01-27
US8507681B2 (en) 2013-08-13
MA33734B1 (fr) 2012-11-01
KR101550557B1 (ko) 2015-09-04
NZ599815A (en) 2013-04-26
PT2499139E (pt) 2014-02-10
AU2010317501A1 (en) 2012-05-17
PH12012500903A1 (en) 2014-09-24
TWI394756B (zh) 2013-05-01
KR20120099460A (ko) 2012-09-10
HK1173724A1 (en) 2013-05-24
US8802690B2 (en) 2014-08-12
ES2444543T3 (es) 2014-02-25
CU20120071A7 (es) 2013-05-31
HRP20140025T1 (hr) 2014-02-14
TN2012000192A1 (fr) 2013-12-12
IL219373A0 (en) 2012-06-28
ZA201204231B (en) 2013-02-27
WO2011058474A1 (fr) 2011-05-19
CA2778886C (fr) 2014-01-07
EA201290191A1 (ru) 2012-12-28
PL2499139T3 (pl) 2014-04-30
SI2499139T1 (sl) 2014-01-31
EP2676958B1 (fr) 2015-07-01
JP2013510192A (ja) 2013-03-21
CR20120190A (es) 2012-05-24
IL219373A (en) 2014-04-30
US9139587B2 (en) 2015-09-22
EA020153B1 (ru) 2014-09-30
US20130030181A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
ZA201204231B (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT2621493T (pt) Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
ZA201303882B (en) N1/n2-lactam acetyl-coa carboxylase inhibitors
GB2474952B (en) Level
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
IL198779A0 (en) Spiroketone acetyl-coa carboxylase inhibitors
EP2552208A4 (fr) Imidazolyl-imidazoles en tant qu'inhibiteurs de kinase
EP2552214A4 (fr) Pyrazolyl-pyrimidines utilisés en tant qu'inhibiteurs de kinase
EP2552211A4 (fr) Indazolyl-pyrimidines utilisés en tant qu'inhibiteurs de kinase
AP3499A (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
EP2443235A4 (fr) Variants de -glucosidase
GB201009731D0 (en) Kinase inhibitors
GB0917559D0 (en) Surgicalinstruments
GB0916010D0 (en) JMJD2 demethylase inhibitors
GB0914726D0 (en) Kinase inhibitors
GB201104990D0 (en) Screw-fix level
GB0902661D0 (en) Inhibitors
GB0903650D0 (en) Glyoalase inhibitors
GB0915927D0 (en) Novel inhibitors
GB201018597D0 (en) Inhibitors
GB201003936D0 (en) Novel inhibitors
GB201006605D0 (en) Novel inhibitors
GB201003502D0 (en) Novel inhibitors